Piramal Pharma Ltd.
PPLPHARMA · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹141.98.
Piotroski F-score 2/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%-4.0%
- ✕Low debt (D/E < 0.5)0.70x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-0%
- –Earnings growing
- ✕Net margin ≥ 10%-3.7%
- ✓Current ratio > 1.51.51
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✕Altman Z in safe zoneZ 2.1
- ✕Piotroski ≥ 72/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Weaknesses
- •Low return on equity (-4.0%).
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (2/9).
Opportunities
- •Trading in our value buy zone versus sector peers.
About Piramal Pharma Ltd.
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.